<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339993</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">961</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090961</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with B-lymphocyte malignancies (BCMs) receiving B-lymphocyte-targeted therapies have increased risk of severe COVID-19 outcomes and impaired antibody response to SARS-CoV-2 mRNA vaccination in comparison to non-hematologic oncologic patients or general population. Consequently, it is vital to explore vaccine-induced T-lymphocyte responses in patients referred for the understanding of immune protection against SARS-CoV2 infections. The objective of the present study was to analyze the recall immune responses carried out by T lymphocytes after two COVID-19 mRNA vaccine doses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 40 patients with BCMs and 10 healthy controls (HCs) after 4 weeks from the second mRNA vaccine dose. Spike (S)-specific T-lymphocyte responses were assessed in peripheral blood mononuclear lymphocytes (PBMCs) by intracellular IFN-γ staining combined with flow cytometry. Furthermore, the humoral response was assessed with the measurement of anti-spike antibodies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From March to July 2021, 40 patients (median age 68) received mRNA vaccines. The overall antibody response for BCMs was 52.5% versus 100% for the healthy controls (<i>p</i> = 0.008). The antibody response was different across BCMs: 18.75% for non-Hodgkin lymphoma, 54.5% for chronic lymphocytic leukemia, and 92.3% for multiple myeloma. Responses varied by malignancy type and treatment, with anti-CD20 therapies showing the lowest response (6.7%). T-lymphocyte analysis revealed reduced numbers and altered differentiation stages in patients compared to the controls. However, the vaccine-induced T response was generally robust, with variations in specific T subpopulations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">mRNA vaccines induced significant humoral and cellular immune responses in B-cell lymphoid malignancy patients, although responses varied by treatment type and malignancy. Further research is needed to optimize vaccination strategies in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>García Ramírez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1471-5018</Identifier><AffiliationInfo><Affiliation>Hematology Department, University Hospital "Príncipe de Asturias", Alcalá de Henares, 28805 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callejas Charavia</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital "Príncipe de Asturias", Alcalá de Henares, 28805 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva Martin</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRYCIS Unit (Instituto Ramón y Cajal de Investigación Sanitaria), 28034 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez La Hoz</LastName><ForeName>Ana María</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRYCIS Unit (Instituto Ramón y Cajal de Investigación Sanitaria), 28034 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Miguel Ángel</ForeName><Initials>MÁ</Initials><Identifier Source="ORCID">0000-0003-2588-1708</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRYCIS Unit (Instituto Ramón y Cajal de Investigación Sanitaria), 28034 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García Suárez</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital "Príncipe de Asturias", Alcalá de Henares, 28805 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Álvarez-Mon</LastName><ForeName>Melchor</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1309-7510</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRYCIS Unit (Instituto Ramón y Cajal de Investigación Sanitaria), 28034 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monserrat Sanz</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1775-4645</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRYCIS Unit (Instituto Ramón y Cajal de Investigación Sanitaria), 28034 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LIB 15/2021</GrantID><Agency>Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell lymphoid malignancy</Keyword><Keyword MajorTopicYN="N">CD4+ and CD8+ T lymphocytes</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339993</ArticleId><ArticleId IdType="pmc">PMC11435597</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090961</ArticleId><ArticleId IdType="pii">vaccines12090961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chavez-MacGregor M., Lei X., Zhao H., Scheet P., Giordano S.H. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol. 2022;8:69–78. doi: 10.1001/jamaoncol.2021.5148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mato A.R., Roeker L.E., Lamanna N., Allan J.N., Leslie L., Pagel J.M., Patel K., Osterborg A., Wojenski D., Kamdar M., et al. Outcomes of COVID-19 in patients with CLL: A multicenter international experience. Blood. 2020;136:1134–1143. doi: 10.1182/blood.2020006965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006965</ArticleId><ArticleId IdType="pmc">PMC7472711</ArticleId><ArticleId IdType="pubmed">32688395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chari A., Samur M.K., Martinez-Lopez J., Cook G., Biran N., Yong K., Hungria V., Engelhardt M., Gay F., Feria A.G., et al. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set. Blood. 2020;136:3033–3040. doi: 10.1182/blood.2020008150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008150</ArticleId><ArticleId IdType="pmc">PMC7759145</ArticleId><ArticleId IdType="pubmed">33367546</ArticleId></ArticleIdList></Reference><Reference><Citation>Duléry R., Lamure S., Delord M., Di Blasi R., Chauchet A., Hueso T., Rossi C., Drenou B., Fischer B.D., Soussain C., et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am. J. Hematol. 2021;96:934–944. doi: 10.1002/ajh.26209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26209</ArticleId><ArticleId IdType="pmc">PMC8212109</ArticleId><ArticleId IdType="pubmed">33909916</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L., Salmanton-García J., Marchesi F., Blennow O., Gomes da Silva M., Glenthøj A., van Doesum J., Bilgin Y.M., López-García A., Itri F., et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: Results from the EPICOVIDEHA survey. Blood J. Am. Soc. Hematol. 2022;140:2773–2787. doi: 10.1182/blood.2022017257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022017257</ArticleId><ArticleId IdType="pmc">PMC9492383</ArticleId><ArticleId IdType="pubmed">36126318</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-López J., De la Cruz J., Gil-Manso R., Alegre A., Ortiz J., Llamas P., Martínez Y., Hernández-Rivas J., González-Gascón I., Benavente C., et al. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study. Cancers. 2023;15:1497. doi: 10.3390/cancers15051497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15051497</ArticleId><ArticleId IdType="pmc">PMC10001264</ArticleId><ArticleId IdType="pubmed">36900296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., Wellington E., Khawam J., Munro K., Cole M., et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022;386:1207–1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488.e11. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Donis R.O., Koup R.A., Fong Y., Plotkin S.A., Follmann D. A COVID-19 Milestone Attained—A Correlate of Protection for Vaccines. N. Engl. J. Med. 2022;387:2203–2206. doi: 10.1056/NEJMp2211314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., Morales M., Ziv T., Arbel Y.S., Scarfò L., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. doi: 10.1182/blood.2021011568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011568</ArticleId><ArticleId IdType="pmc">PMC8061088</ArticleId><ArticleId IdType="pubmed">33861303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghione P., Gu J.J., Attwood K., Torka P., Goel S., Sundaram S., Mavis C., Johnson M., Thomas R., McWhite K.M., et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138:811–814. doi: 10.1182/blood.2021012443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012443</ArticleId><ArticleId IdType="pmc">PMC8245303</ArticleId><ArticleId IdType="pubmed">34189565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., Honda A., Kurokawa M. COVID-19 mRNA Vaccine in Patients with Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis. Clin. Lymphoma Myeloma Leuk. 2022;22:e691–e707. doi: 10.1016/j.clml.2022.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2022.03.012</ArticleId><ArticleId IdType="pmc">PMC8958822</ArticleId><ArticleId IdType="pubmed">35459624</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco V., Carniti C., Guidetti A., Farina L., Magni M., Miceli R., Calabretta L., Verderio P., Ljevar S., Serpenti F., et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br. J. Haematol. 2022;196:548–558. doi: 10.1111/bjh.17877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17877</ArticleId><ArticleId IdType="pmc">PMC8653177</ArticleId><ArticleId IdType="pubmed">34649298</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry C., Luttwak E., Balaban R., Shefer G., Morales M.M., Aharon A., Tabib Y., Cohen Y.C., Benyamini N., Beyar-Katz O., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053–3061. doi: 10.1182/bloodadvances.2021005094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005094</ArticleId><ArticleId IdType="pmc">PMC8362658</ArticleId><ArticleId IdType="pubmed">34387648</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens E.M., Ketas T.J., Zhao Z., Satlin M.J., Small C.B., Sukhu A., Francomano E., Klasse P.J., Garcia A., Nguyenduy E., et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am. J. Hematol. 2021;96:E410–E413. doi: 10.1002/ajh.26322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26322</ArticleId><ArticleId IdType="pmc">PMC8420465</ArticleId><ArticleId IdType="pubmed">34390501</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurion R., Rozovski U., Itchaki G., Gafter-Gvili A., Leibovitch C., Raanani P., Ben-Zvi H., Szwarcwort M., Taylor-Abigadol M., Dann E.J., et al. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2022;107:715–720. doi: 10.3324/haematol.2021.279216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.279216</ArticleId><ArticleId IdType="pmc">PMC8883526</ArticleId><ArticleId IdType="pubmed">34320790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurion R., Rozovski U., Itchaki G., Gafter-Gvili A., Leibovitch C., Raanani P., Ben-Zvi H., Szwarcwort M., Taylor-Abigadol M., Dann E.J., et al. Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. Crit. Care. 2021;25:140. doi: 10.1186/s13054-021-03558-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03558-w</ArticleId><ArticleId IdType="pmc">PMC8040759</ArticleId><ArticleId IdType="pubmed">33845874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange E.M., Han N.A., Wileyto P., Kim J.Y., Gouma S., Robinson J., Greenplate A.R., Hwee M.A., Porterfield F., Owoyemi O., et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021;27:1280–1289. doi: 10.1038/s41591-021-01386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers E., Canderan G., Williams M.E., Keshavarz B., Portell C.A., Wilson J.M., Woodfolk J.A. In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms. Blood Cancer J. 2023;13:114. doi: 10.1038/s41408-023-00884-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-023-00884-w</ArticleId><ArticleId IdType="pmc">PMC10372059</ArticleId><ArticleId IdType="pubmed">37495573</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanackovic D., Luetkens T., Omili D., Iraguha T., Lutfi F., Hardy N.M., Fan X., Avila S.V., Saharia K.K., Husson J.S., et al. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood. 2022;140:152–156. doi: 10.1182/blood.2022016175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016175</ArticleId><ArticleId IdType="pmc">PMC9135504</ArticleId><ArticleId IdType="pubmed">35537186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfannes R., Pierzchalski A., Maddalon A., Simion A., Zouboulis C.C., Behre G., Zenclussen A.C., Westphal S., Fest S., Herberth G. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments. Front. Immunol. 2023;14:1087996. doi: 10.3389/fimmu.2023.1087996.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1087996</ArticleId><ArticleId IdType="pmc">PMC10177659</ArticleId><ArticleId IdType="pubmed">37187728</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Muftuoglu M., Liang S., Basyal M., Lv J., Akdogan M.E., Chen K., Andreeff M., Flowers C.R., Parmar S. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight. 2022;7:e156559. doi: 10.1172/jci.insight.156559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.156559</ArticleId><ArticleId IdType="pmc">PMC9057595</ArticleId><ArticleId IdType="pubmed">35230977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouhani S.J., Yu J., Olson D., Zha Y., Pezeshk A., Cabanov A., Pyzer A.R., Trujillo J., A Derman B., O’Donnell P., et al. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J. Immunother. Cancer. 2022;10:e004766. doi: 10.1136/jitc-2022-004766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2022-004766</ArticleId><ArticleId IdType="pmc">PMC9226983</ArticleId><ArticleId IdType="pubmed">35732350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann-Horn K., Schleich E., Hertzenberg D., Hapfelmeier A., Kümpfel T., von Bubnoff N., Hohlfeld R., Berthele A., Hemmer B., Weber M.S. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J. Neuroinflamm. 2011;8:146. doi: 10.1186/1742-2094-8-146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-146</ArticleId><ArticleId IdType="pmc">PMC3214191</ArticleId><ArticleId IdType="pubmed">22027448</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry J.Y., Labarthe M.-C., Meyer B., Dasgupta P., Dalgleish A.G., Galustian C. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139:377–385. doi: 10.1111/imm.12087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12087</ArticleId><ArticleId IdType="pmc">PMC3701184</ArticleId><ArticleId IdType="pubmed">23374145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rodriguez A.P., Contesti J., Huergo-Zapico L., Lopez-Soto A., Fernández-Guizán A., Acebes-Huerta A., Gonzalez-Huerta A.J., Gonzalez E., Fernandez-Alvarez C., Gonzalez S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk. Lymphoma. 2010;51:1829–1836. doi: 10.3109/10428194.2010.503820.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2010.503820</ArticleId><ArticleId IdType="pubmed">20846097</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma M., Gentilcore G., Heimersson K., Mozaffari F., Näsman-Glaser B., Young E., Rosenquist R., Hansson L., Österborg A., Mellstedt H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562–572. doi: 10.3324/haematol.2016.151100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2016.151100</ArticleId><ArticleId IdType="pmc">PMC5394965</ArticleId><ArticleId IdType="pubmed">27927767</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bruggen J.A.C., Martens A.W.J., Tonino S.H., Kater A.P. Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837. Cancers. 2021;13:4738. doi: 10.3390/cancers13194738.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13194738</ArticleId><ArticleId IdType="pmc">PMC8507522</ArticleId><ArticleId IdType="pubmed">34638518</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis S.A., Kakara M., Painter M.M., Goel R.R., Mathew D., Lenzi K., Rezk A., Patterson K.R., Espinoza D.A., Kadri J.C., et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 2021;27:1990–2001. doi: 10.1038/s41591-021-01507-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01507-2</ArticleId><ArticleId IdType="pmc">PMC8604727</ArticleId><ArticleId IdType="pubmed">34522051</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh B.L.Z., Tan N., de Alwis R., Kunasegaran K., Chen Z., Poon M., Chan E., Low J.G.H., Yeoh A.E.J., Bertoletti A., et al. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. Blood. 2022;140:156–160. doi: 10.1182/blood.2022016166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016166</ArticleId><ArticleId IdType="pmc">PMC9281508</ArticleId><ArticleId IdType="pubmed">35472242</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzolo M.C., Del Giudice I., Peragine N., Mariglia P., De Propris M.S., Cappelli L.V., Trentin L., Reda G., Cuneo A., Molica S., et al. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Front. Oncol. 2021;11:637186. doi: 10.3389/fonc.2021.637186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.637186</ArticleId><ArticleId IdType="pmc">PMC8082026</ArticleId><ArticleId IdType="pubmed">33937038</ArticleId></ArticleIdList></Reference><Reference><Citation>Solman I.G., Blum L.K., Burger J.A., Kipps T.J., Dean J.P., James D.F., Mongan A. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk. Res. 2021;102:106520. doi: 10.1016/j.leukres.2021.106520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2021.106520</ArticleId><ArticleId IdType="pubmed">33611131</ArticleId></ArticleIdList></Reference><Reference><Citation>Renrick A.N., Thounaojam M.C., de Aquino M.T.P., Chaudhuri E., Pandhare J., Dash C., Shanker A. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. Front. Immunol. 2021;12:607044. doi: 10.3389/fimmu.2021.607044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.607044</ArticleId><ArticleId IdType="pmc">PMC7946819</ArticleId><ArticleId IdType="pubmed">33717088</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690–714. doi: 10.1016/j.ccell.2015.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2015.10.012</ArticleId><ArticleId IdType="pubmed">26678337</ArticleId></ArticleIdList></Reference><Reference><Citation>Re D., Seitz-Polski B., Brglez V., Carles M., Graça D., Benzaken S., Liguori S., Zahreddine K., Delforge M., Bailly-Maitre B., et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat. Commun. 2022;13:864. doi: 10.1038/s41467-022-28578-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28578-0</ArticleId><ArticleId IdType="pmc">PMC8844396</ArticleId><ArticleId IdType="pubmed">35165284</ArticleId></ArticleIdList></Reference><Reference><Citation>Re D., Seitz-Polski B., Brglez V., Carles M., Graça D., Benzaken S., Liguori S., Zahreddine K., Delforge M., Bailly-Maitre B., et al. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci. Immunol. 2022;7:eadd3899. doi: 10.1126/sciimmunol.add3899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add3899</ArticleId><ArticleId IdType="pmc">PMC9798886</ArticleId><ArticleId IdType="pubmed">36318037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Kilian C., Turner J.-E., Bosurgi L., Roedl K., Bartsch P., Gnirck A.-C., Cortesi F., Schultheiß C., Hellmig M., et al. Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients. Sci. Immunol. 2021;6:eabf6692. doi: 10.1126/sciimmunol.abf6692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf6692</ArticleId><ArticleId IdType="pmc">PMC8128299</ArticleId><ArticleId IdType="pubmed">33622974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P.A., Minervina A.A., Pogorelyy M.V., Turner J.S., Kim W., Kalaidina E., Petersen J., Schmitz A.J., Lei T., Haile A., et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell. 2022;185:603–613.e15. doi: 10.1016/j.cell.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>